Abstract

Senescent cells accumulate in fat with aging. We previously found genetic clearance of senescent cells from progeroid INK-ATTAC mice prevents lipodystrophy. Here we show that primary human senescent fat progenitors secrete activin A and directly inhibit adipogenesis in non-senescent progenitors. Blocking activin A partially restored lipid accumulation and expression of key adipogenic markers in differentiating progenitors exposed to senescent cells. Mouse fat tissue activin A increased with aging. Clearing senescent cells from 18-month-old naturally-aged INK-ATTAC mice reduced circulating activin A, blunted fat loss, and enhanced adipogenic transcription factor expression within 3 weeks. JAK inhibitor suppressed senescent cell activin A production and blunted senescent cell-mediated inhibition of adipogenesis. Eight weeks-treatment with ruxolitinib, an FDA-approved JAK1/2 inhibitor, reduced circulating activin A, preserved fat mass, reduced lipotoxicity, and increased insulin sensitivity in 22-month-old mice. Our study indicates targeting senescent cells or their products may alleviate age-related dysfunction of progenitors, adipose tissue, and metabolism.

Article and author information

Author details

  1. Ming Xu

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  2. Allyson K Palmer

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    Allyson K Palmer, This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.
  3. Husheng Ding

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  4. Megan M Weivoda

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  5. Tamar Pirtskhalava

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    Tamar Pirtskhalava, This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.
  6. Thomas A White

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  7. Anna Sepe

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  8. Kurt O Johnson

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  9. Michael B Stout

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  10. Nino Giorgadze

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    Nino Giorgadze, This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.
  11. Michael D Jensen

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  12. Nathan K LeBrasseur

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  13. Tamar Tchkonia

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    Competing interests
    Tamar Tchkonia, This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.
  14. James L Kirkland

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, United States
    For correspondence
    Kirkland.James@mayo.edu
    Competing interests
    James L Kirkland, This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.

Reviewing Editor

  1. Andrew Dillin, Howard Hughes Medical Institute, University of California, Berkeley, United States

Ethics

Animal experimentation: Experimental procedures (A21013, A37715 and A16315) were approved by the IACUC at Mayo Clinic

Human subjects: The protocol (10-005236) was approved by the Mayo Clinic Foundation Institutional Review Board for Human Research. Informed consent and consent to publish was obtained from all human subjects.

Version history

  1. Received: November 13, 2015
  2. Accepted: December 18, 2015
  3. Accepted Manuscript published: December 19, 2015 (version 1)
  4. Version of Record published: February 4, 2016 (version 2)
  5. Version of Record updated: September 22, 2016 (version 3)

Copyright

© 2015, Xu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,943
    views
  • 2,344
    downloads
  • 421
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ming Xu
  2. Allyson K Palmer
  3. Husheng Ding
  4. Megan M Weivoda
  5. Tamar Pirtskhalava
  6. Thomas A White
  7. Anna Sepe
  8. Kurt O Johnson
  9. Michael B Stout
  10. Nino Giorgadze
  11. Michael D Jensen
  12. Nathan K LeBrasseur
  13. Tamar Tchkonia
  14. James L Kirkland
(2015)
Targeting senescent cells enhances adipogenesis and metabolic function in old age
eLife 4:e12997.
https://doi.org/10.7554/eLife.12997

Share this article

https://doi.org/10.7554/eLife.12997

Further reading

    1. Developmental Biology
    Rieko Asai, Vivek N Prakash ... Takashi Mikawa
    Research Article

    Large-scale cell flow characterizes gastrulation in animal development. In amniote gastrulation, particularly in avian gastrula, a bilateral vortex-like counter-rotating cell flow, called ‘polonaise movements’, appears along the midline. Here, through experimental manipulations, we addressed relationships between the polonaise movements and morphogenesis of the primitive streak, the earliest midline structure in amniotes. Suppression of the Wnt/planar cell polarity (PCP) signaling pathway maintains the polonaise movements along a deformed primitive streak. Mitotic arrest leads to diminished extension and development of the primitive streak and maintains the early phase of the polonaise movements. Ectopically induced Vg1, an axis-inducing morphogen, generates the polonaise movements, aligned to the induced midline, but disturbs the stereotypical cell flow pattern at the authentic midline. Despite the altered cell flow, induction and extension of the primitive streak are preserved along both authentic and induced midlines. Finally, we show that ectopic axis-inducing morphogen, Vg1, is capable of initiating the polonaise movements without concomitant PS extension under mitotic arrest conditions. These results are consistent with a model wherein primitive streak morphogenesis is required for the maintenance of the polonaise movements, but the polonaise movements are not necessarily responsible for primitive streak morphogenesis. Our data describe a previously undefined relationship between the large-scale cell flow and midline morphogenesis in gastrulation.

    1. Computational and Systems Biology
    2. Developmental Biology
    Arya Y Nakhe, Prasanna K Dadi ... David A Jacobson
    Research Article

    The gain-of-function mutation in the TALK-1 K+ channel (p.L114P) is associated with maturity-onset diabetes of the young (MODY). TALK-1 is a key regulator of β-cell electrical activity and glucose-stimulated insulin secretion. The KCNK16 gene encoding TALK-1 is the most abundant and β-cell-restricted K+ channel transcript. To investigate the impact of KCNK16 L114P on glucose homeostasis and confirm its association with MODY, a mouse model containing the Kcnk16 L114P mutation was generated. Heterozygous and homozygous Kcnk16 L114P mice exhibit increased neonatal lethality in the C57BL/6J and the CD-1 (ICR) genetic background, respectively. Lethality is likely a result of severe hyperglycemia observed in the homozygous Kcnk16 L114P neonates due to lack of glucose-stimulated insulin secretion and can be reduced with insulin treatment. Kcnk16 L114P increased whole-cell β-cell K+ currents resulting in blunted glucose-stimulated Ca2+ entry and loss of glucose-induced Ca2+ oscillations. Thus, adult Kcnk16 L114P mice have reduced glucose-stimulated insulin secretion and plasma insulin levels, which significantly impairs glucose homeostasis. Taken together, this study shows that the MODY-associated Kcnk16 L114P mutation disrupts glucose homeostasis in adult mice resembling a MODY phenotype and causes neonatal lethality by inhibiting islet insulin secretion during development. These data suggest that TALK-1 is an islet-restricted target for the treatment for diabetes.